RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Theravance Biopharma - Stock

Theravance Biopharma Revenue 2024

Theravance Biopharma Revenue

73.93 M USD

Ticker

TBPH

ISIN

KYG8807B1068

WKN

A1137V

In 2024, Theravance Biopharma's sales reached 73.93 M USD, a 28.74% difference from the 57.42 M USD sales recorded in the previous year.

The Theravance Biopharma Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e306.7923,44
2028e218.7532,87
2027e154.5346,53
2026e131.9954,47
2025e82.8986,74
2024e73.9397,26
202357.42125,21
202251.3140,16
202155.3130,02
202071.9100,00
201973.4100,00
201860.498,84
201715.461,04
201648.694,24
201542.189,07
201411.764,96
20130.235950,00
2012130.155,27
201114.9482,55

Theravance Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Theravance Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Theravance Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Theravance Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Theravance Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Theravance Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Theravance Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Theravance Biopharma’s growth potential.

Theravance Biopharma Revenue, Profit, and EBIT History

DateTheravance Biopharma RevenueTheravance Biopharma EBITTheravance Biopharma Net Income
2029e306.79 M undefined0 undefined263.89 M undefined
2028e218.75 M undefined81.84 M undefined173.11 M undefined
2027e154.53 M undefined17.96 M undefined93 M undefined
2026e131.99 M undefined-9.18 M undefined42.39 M undefined
2025e82.89 M undefined-19.83 M undefined6.12 M undefined
2024e73.93 M undefined-23.93 M undefined-32.31 M undefined
202357.42 M undefined-53.29 M undefined-55.19 M undefined
202251.3 M undefined-79.1 M undefined872.1 M undefined
202155.3 M undefined-237.7 M undefined-199.4 M undefined
202071.9 M undefined-297.6 M undefined-278 M undefined
201973.4 M undefined-251.9 M undefined-236.5 M undefined
201860.4 M undefined-238.8 M undefined-215.5 M undefined
201715.4 M undefined-260.1 M undefined-285.4 M undefined
201648.6 M undefined-180.5 M undefined-190.7 M undefined
201542.1 M undefined-181.9 M undefined-182.2 M undefined
201411.7 M undefined-232.5 M undefined-237 M undefined
2013200,000 undefined-156.3 M undefined-156.3 M undefined
2012130.1 M undefined-9.6 M undefined-9.6 M undefined
201114.9 M undefined-109.3 M undefined-109.3 M undefined

Theravance Biopharma stock margins

The Theravance Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Theravance Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Theravance Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Theravance Biopharma's sales revenue. A higher gross margin percentage indicates that the Theravance Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Theravance Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Theravance Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Theravance Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Theravance Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Theravance Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Theravance Biopharma Margin History

Theravance Biopharma Gross marginTheravance Biopharma Profit marginTheravance Biopharma EBIT marginTheravance Biopharma Profit margin
2029e100 %0 %86.02 %
2028e100 %37.41 %79.14 %
2027e100 %11.62 %60.19 %
2026e100 %-6.95 %32.11 %
2025e100 %-23.92 %7.38 %
2024e100 %-32.37 %-43.7 %
2023100 %-92.8 %-96.11 %
2022100 %-154.19 %1,700 %
2021100 %-429.84 %-360.58 %
2020100 %-413.91 %-386.65 %
2019100 %-343.19 %-322.21 %
201898.84 %-395.36 %-356.79 %
201761.04 %-1,688.96 %-1,853.25 %
201694.24 %-371.4 %-392.39 %
201589.07 %-432.07 %-432.78 %
201464.96 %-1,987.18 %-2,025.64 %
2013100 %-78,150 %-78,150 %
2012100 %-7.38 %-7.38 %
2011100 %-733.56 %-733.56 %

Theravance Biopharma Aktienanalyse

What does Theravance Biopharma do?

Theravance Biopharma Inc is a company that was founded in 2014 and is headquartered in South San Francisco, California. The company is a spin-off of Theravance Inc, which was founded in 1996 and specialized in the development of drugs for respiratory diseases and infections. The business model of Theravance Biopharma is to develop and market innovative drugs for severe respiratory diseases, infections, and immunological disorders. The company works closely with its partners and scientific network to discover, develop, and market new drugs. Theravance Biopharma is divided into several business units, including Theravance Biopharma R&D, which focuses on drug discovery and development, and Theravance Biopharma Commercialization, which focuses on marketing Theravance's products. The company has developed and launched a number of products, including the branded products Vibativ and Velusetrag. Vibativ is an antibiotic used to treat severe lung infections and other infections, while Velusetrag was developed for the treatment of chronic constipation in patients with gastrointestinal disorders such as irritable bowel syndrome. The company also has a broad pipeline of products in various stages of development. This includes drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD), autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis, as well as infections such as MRSA and pneumococcal. Theravance Biopharma has also formed a strong partnership with GSK (GlaxoSmithKline), one of the world's leading pharmaceutical companies. The two companies are working together to develop drugs to help patients with severe respiratory diseases, infections, and immune disorders. In summary, Theravance Biopharma is an innovative company that focuses on the discovery, development, and commercialization of drugs for the treatment of severe respiratory diseases, infections, and immune disorders. The company has a strong pipeline of products in various stages of development and a strong partnership with GSK to continue providing innovative solutions for patients with severe illnesses. Theravance Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Theravance Biopharma's Sales Figures

The sales figures of Theravance Biopharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Theravance Biopharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Theravance Biopharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Theravance Biopharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Theravance Biopharma Stock

How much revenue did Theravance Biopharma generate this year?

Theravance Biopharma has achieved a revenue of 73.93 M USD this year.

How much was the turnover of the company Theravance Biopharma compared to the previous year?

The revenue of Theravance Biopharma has increased by 28.74% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Theravance Biopharma?

The revenue of Theravance Biopharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Theravance Biopharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Theravance Biopharma so important for investors?

The revenue of Theravance Biopharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Theravance Biopharma pay?

Over the past 12 months, Theravance Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theravance Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Theravance Biopharma?

The current dividend yield of Theravance Biopharma is .

When does Theravance Biopharma pay dividends?

Theravance Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Theravance Biopharma?

Theravance Biopharma paid dividends every year for the past 0 years.

What is the dividend of Theravance Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Theravance Biopharma located?

Theravance Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Theravance Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Theravance Biopharma from 6/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/20/2024.

When did Theravance Biopharma pay the last dividend?

The last dividend was paid out on 6/20/2024.

What was the dividend of Theravance Biopharma in the year 2023?

In the year 2023, Theravance Biopharma distributed 0 USD as dividends.

In which currency does Theravance Biopharma pay out the dividend?

The dividends of Theravance Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Theravance Biopharma

Our stock analysis for Theravance Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theravance Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.